Companies & People
Tenax narrows next Phase 3 trial after LEVEL misses main goal
CHAPEL HILL - Tenax Therapeutics plans to narrow enrollment in its next Phase 3 trial after TNX-103 missed the primary and key secondary endpoints in the LEVEL study,…